Osteosarcoma, From Lab to Trial

Jason Yustein, M.D., Ph.D., has spent years studying osteosarcoma, the most common bone cancer in kids and teens.

Osteosarcoma is tough because it spreads fast and often comes back after treatment. For kids who relapse, time matters. 

Thanks to early and continued funding from Rally Foundation for Childhood Cancer Research, first at Baylor College of Medicine and now at Emory University, Dr. Yustein and his team found new possible ways to stop osteosarcoma.

One of the most exciting results is a drug called Tegavivint, which slowed tumor growth in lab tests.

Now, Tegavivint is being tested in children and teens through a clinical trial at hospitals across North America. 

Because Rally took a chance on early-stage research, Dr. Yustein’s work has also: 

• Led to published findings in top scientific journals.
• Brought in over $4 million in new funding from the National Cancer Institute, the Department of Defense and other sources.
• Created new mouse models of osteosarcoma that researchers across the world are now using to find cures faster.

This is why early-stage research funding matters. 

This is the power of philanthropic seed investing. 

This is Rally.